Mandated: COVID-19 Vaccine for all participants
The field of complement drug discovery has never been riper with opportunities for therapeutic intervention in diverse clinical indications. 14 years after the clinical approval of the first complement-specific drug, eculizumab, the complement drug space has garnered renewed interest owing to a series of game-changing clinical developments. The recent clinical approval of the first compstatin-based C3-targeted therapeutic for treating PNH and the approval of a small-molecule C5aR1 antagonist for severe ANCA-associated vasculitis have expanded the clinical arsenal of complement therapeutics bringing tailored complement intervention closer to fruition and bolstering confidence in the broader therapeutic scope of complement inhibitors.
Embracing these important developments, we are delighted to announce the 14th International Conference on Complement Therapeutics which will bring together leading experts from academia, the biopharma industry and drug regulatory agencies to discuss the latest developments in complement therapeutics, clinical trials and new aspects of complement-driven pathophysiology in emerging indications. Topics will include: Molecular mechanisms and targets in complement-related diseases; Novel inhibitors & pipeline compounds; Hematological disorders; Organ & cell transplantation, I/R injury and chronic rejection; Kidney diseases; Neurological & ocular diseases; Acute and chronic inflammatory disorders; Infectious diseases & COVID-19; complement targeting in cancer immunotherapy; complement biomarkers in disease diagnosis and therapy; Novel and unexpected indications.